{"product_id":"9783527345717","title":"Principles of Biomedical Sciences and Industry : Translating Ideas into Treatments","description":"\u003cp\u003eThis practical guide to four major areas within the biomedical industry (pharmaceuticals, diagnostics, biomaterials, medical devices) covers the entire product lifecycle, from translating a scientific result into a prototype to product launch and portfolio management. Biopharmaceutical Innovation at a Glance\n\u003cbr\u003ePharmacology and Drug Targets - The Basis of Therapeutics\n\u003cbr\u003ePrinciples and Methods of the Pharmaceutical Drug Discovery Process - From Idea over Target to a Development Candidate\n\u003cbr\u003eBiomarkers - Definitions and Utility for Drug Development\n\u003cbr\u003eToxicology and Managaing Safety and Risks\n\u003cbr\u003eIntroduction to Chemistry Manufacturing and Controls - From Compound and Development Candidate to Drug\n\u003cbr\u003eTranslational Medicine - The Bridging Discipline: Role and Tools in the Drug Development Process\n\u003cbr\u003eDecision-Making - What Are the Key Drivers Around Decision-Making in Drug Development?\n\u003cbr\u003eClinical Drug Development - Clinical Characterization for Regulatory Approval\n\u003cbr\u003eRegulatory Affairs - Communicating with Health Authorities\n\u003cbr\u003eRegulatory Affairs in Device Development - How to Design Medical Devices Capable to Enter the Market\n\u003cbr\u003eMarket Entry and Reimbursement - Making Drugs Available for Patients After Drug Approval\n\u003cbr\u003ePricing in Germany - Key Learnings for Optimising Price Potential After the Introduction of AMNOG\n\u003cbr\u003eProject, Risk and Portfolio Management - Managing R\u0026amp;D Project Costs and Risks\n\u003cbr\u003eIntellectual Property - How to Protect Innovation in the Biopharmaceutical Industry\n\u003cbr\u003ePatents in the Biomedical Sciences and Industry - The Case of Swiss Life Science Company Prionics\n\u003cbr\u003ePharmaceutical Business Development \u0026amp; Licensing - Overview of a Cross-functional and Multifaceted Role and Its Key Elements in Biopharmaceutical Industry\n\u003cbr\u003eThe Entrepreneur's Guide Through the Galaxy of Biotech Funding\n\u003cbr\u003eMedical Technologies - Key Learning from Two Case Studies\n\u003cbr\u003eDiagnostics - Tools for Clinical Decision Making and Clinical Trial Endpoints\n\u003cbr\u003eVaccination - Towards an Improved Influenza Vaccine\n\u003cbr\u003e Markus Hinder studied medicine at the Universities of Heidelberg, Paris and Zürich and obtained a doctoral degree in pharmacology from Heidelberg University. After graduation he trained in clinical pharmacology, cardiology and emergency medicine. He underwent postgraduate training in clinical trial methodology and statistics at the Universities of Basel and Brussels. He joined the pharmaceutical industry more than 20 years ago and held senior leadership positions in clinical pharmacology, translational medicine, clinical development, medical affairs and project management. He has been lecturing pharmacology and pharmaceutical R\u0026amp;D since 2004. In 2010 he was appointed professor at Cardiff University\/ Hochschule Fresenius. He serves as a reviewer for several journals and associate editor for the Journal of Translational Medicine.\n\u003cbr\u003e \n\u003cbr\u003eAlexander Schuhmacher graduated in biology from the University of Konstanz (Germany), in pharmaceutical medicine at the University of Witten\/Herdecke (Germany) and did a Ph.D. in molecular biology at the University of Konstanz; he is also a graduate of the Executive MBA program at the University of St. Gallen (Switzerland). Alexander holds a full professorship in life science management at the Technische Hochschule Ingolstadt (Germany). His research focus is on biopharmaceutical innovation management with a specialization on R\u0026amp;D efficiency, artificial intelligence and open innovation. Prior to that, Alexander worked 9 years as professor at Reutlingen University (Germany) and 14 years in various R\u0026amp;D leadership positions in the pharmaceutical industry.\n\u003cbr\u003e \n\u003cbr\u003eJörg Goldhahn received his M.D. 1997 from the Friedrich-Schiller University in Jena, Germany, finished a postgraduate course (MAS) in Medical Physics and Biomechanics at the ETH Zurich in 2000, received the postdoctoral lecture qualification (Habilitation) in 2008 and became a faculty member of the department for health sciences and technology (D-HEST) as adjunct professor 2014. He worked as a translational medicine expert at the Novartis Institutes for Biomedical Research (NIBR) in Basel in addition to more than 15 years in clinical research. He is currently the head of the Institute for Translational Medicine and medical director of the bachelor in medicine at ETH in Zurich, Switzerland.\n\u003cbr\u003e \n\u003cbr\u003eDominik Hartl studied Medicine at the Universities of Regensburg, Munich and Melbourne and obtained his doctoral degree in Immunology from Munich\/LMU University. He is board certified in Pediatrics and Infectious Diseases and worked as Physician Scientist\/Post-Doc Scholar at Yale University. He joined the pharmaceutical industry more than 6 years ago and gained extensive experience in his positions in Drug Discovery, Translational Medicine, Biomarkers and Precision Medicine\/Personalized Healthcare in Biotech and Big Pharma. In addition to working in the pharmaceutical industry, Dominik is a Professor for Pediatric Immunology\/Infectious Diseases at the University of Tübingen.\u003c\/p\u003e","brand":"Wiley-VCH","offers":[{"title":"Default Title","offer_id":48224567361771,"sku":"EB_KG0300_F10-06_SIMS","price":172.22,"currency_code":"SGD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0758\/4484\/5803\/files\/9783527345717-1.jpg?v=1781722718","url":"https:\/\/kinokuniya.com.sg\/zh\/products\/9783527345717","provider":"Books Kinokuniya Singapore","version":"1.0","type":"link"}